BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 36348154)

  • 1. Cost-Utility Analysis of Universal Maternal Pertussis Immunisation in Thailand: A Comparison of Two Model Structures.
    Botwright S; Win EM; Kapol N; Benjawan S; Teerawattananon Y
    Pharmacoeconomics; 2023 Jan; 41(1):77-91. PubMed ID: 36348154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of universal maternal immunization with tetanus-diphtheria-acellular pertussis (Tdap) vaccine in Brazil.
    Sartori AMC; de Soárez PC; Fernandes EG; Gryninger LCF; Viscondi JYK; Novaes HMD
    Vaccine; 2016 Mar; 34(13):1531-1539. PubMed ID: 26899375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of pertussis vaccination during pregnancy in Japan.
    Hoshi SL; Seposo X; Okubo I; Kondo M
    Vaccine; 2018 Aug; 36(34):5133-5140. PubMed ID: 30041878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the impact of a continued maternal pertussis immunisation programme in England: A modelling study and cost-effectiveness analysis.
    Sandmann F; Jit M; Andrews N; Buckley HL; Campbell H; Ribeiro S; Sile B; Stowe J; Tessier E; Ramsay M; Amirthalingam G; Choi YH
    Vaccine; 2021 Jul; 39(32):4500-4509. PubMed ID: 34183204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic Evaluation of Human Rotavirus Vaccine in Thailand.
    Saokaew S; Prasitsuebsai W; Bibera GL; Kengkla K; Zhang XH; Oh KB; Lee C
    Infect Dis Ther; 2019 Sep; 8(3):397-415. PubMed ID: 31197662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand.
    Dilokthornsakul P; Kengkla K; Saokaew S; Permsuwan U; Techasaensiri C; Chotpitayasunondh T; Chaiyakunapruk N
    Vaccine; 2019 Jul; 37(32):4551-4560. PubMed ID: 31280944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic impact of implementing decennial tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccination in adults in the United States.
    Havers FP; Cho BH; Walker JW; Hariri S
    Vaccine; 2020 Jan; 38(2):380-387. PubMed ID: 31676198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetanus, diphtheria and acellular pertussis (Tdap) vaccine for prevention of pertussis among adults aged 19 years and older in the United States: A cost-effectiveness analysis.
    Cho BH; Acosta AM; Leidner AJ; Faulkner AE; Zhou F
    Prev Med; 2020 May; 134():106066. PubMed ID: 32199910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing adolescent immunization options for pertussis in Canada: A cost-utility analysis.
    Anyiwe K; Richardson M; Brophy J; Sander B
    Vaccine; 2020 Feb; 38(7):1825-1833. PubMed ID: 31889607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly.
    McGarry LJ; Krishnarajah G; Hill G; Skornicki M; Pruttivarasin N; Masseria C; Arondekar B; Pelton SI; Weinstein MC
    PLoS One; 2013; 8(9):e67260. PubMed ID: 24019859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pertussis vaccination in pregnancy in Canada: a cost-utility analysis.
    Abu-Raya B; Coyle D; Bettinger JA; Vaudry W; Halperin SA; Sadarangani M;
    CMAJ Open; 2020; 8(4):E651-E658. PubMed ID: 33077536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pertussis infant morbidity and mortality trends after universal maternal immunisation in Mexico: An ecological database study with time-series analysis.
    Guzman-Holst A; Luna-Casas G; Cervantes-Apolinar MY; Huerta-Garcia GC; Juliao P; Sánchez-González G
    Vaccine; 2021 Apr; 39(16):2311-2318. PubMed ID: 33773845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Tdap vaccination of adults aged ≥65 years in the prevention of pertussis in the US: a dynamic model of disease transmission.
    McGarry LJ; Krishnarajah G; Hill G; Masseria C; Skornicki M; Pruttivarasin N; Arondekar B; Roiz J; Pelton SI; Weinstein MC
    PLoS One; 2014; 9(1):e72723. PubMed ID: 24416118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pertussis in adolescents and adults: should we vaccinate?
    Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
    Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness and programmatic benefits of maternal vaccination against pertussis in England.
    van Hoek AJ; Campbell H; Amirthalingam G; Andrews N; Miller E
    J Infect; 2016 Jul; 73(1):28-37. PubMed ID: 27108802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroprevalence of Bordetella pertussis antibodies and anti-pertussis antibody response after a single dose of reduced-antigen combined diphtheria, tetanus, and acellular pertussis vaccine (Tdap) in pregnant Thai women.
    Sompagdee N; Anuwutnavin S; Phongsamart W; Senawong S; Umrod P; Robkhonburi A
    Vaccine; 2020 Mar; 38(12):2725-2733. PubMed ID: 32070680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
    Sricharoenchai S; Sirivichayakul C; Chokephaibulkit K; Pitisuttithum P; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chinwangso P; Poredi IK; Petre J; Thai PH; Viviani S
    Lancet Infect Dis; 2018 Jan; 18(1):58-67. PubMed ID: 29066131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of pertussis booster vaccination for preschool children in Japan.
    Tanaka M; Okubo R; Hoshi SL; Ishikawa N; Kondo M
    Vaccine; 2022 Feb; 40(7):1010-1018. PubMed ID: 35039195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact and cost-effectiveness of a second tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine dose to prevent pertussis in the United States.
    Kamiya H; Cho BH; Messonnier ML; Clark TA; Liang JL
    Vaccine; 2016 Apr; 34(15):1832-8. PubMed ID: 26899377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness and budget impact analyses for the prioritisation of the four available rotavirus vaccines in the national immunisation programme in Thailand.
    Luangasanatip N; Mahikul W; Poovorawan K; Cooper BS; Lubell Y; White LJ; Teerawattananon Y; Pan-Ngum W
    Vaccine; 2021 Mar; 39(9):1402-1414. PubMed ID: 33531197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.